HomeCompareTVFCF vs ABBV

TVFCF vs ABBV: Dividend Comparison 2026

TVFCF yields 6.96% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $70.6K in total portfolio value
10 years
TVFCF
TVFCF
● Live price
6.96%
Share price
$9.75
Annual div
$0.68
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$1,083.86
Full TVFCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TVFCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTVFCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TVFCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TVFCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TVFCF
Annual income on $10K today (after 15% tax)
$591.95/yr
After 10yr DRIP, annual income (after tax)
$921.28/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,134.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TVFCF + ABBV for your $10,000?

TVFCF: 50%ABBV: 50%
100% ABBV50/50100% TVFCF
Portfolio after 10yr
$67.0K
Annual income
$12,927.81/yr
Blended yield
19.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TVFCF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
1.7
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TVFCF buys
0
ABBV buys
0
No recent congressional trades found for TVFCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTVFCFABBV
Forward yield6.96%3.06%
Annual dividend / share$0.68$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$31.7K$102.3K
Annual income after 10y$1,083.86$24,771.77
Total dividends collected$8.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TVFCF vs ABBV ($10,000, DRIP)

YearTVFCF PortfolioTVFCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,396$696.41$11,550$430.00$154.00ABBV
2$12,936$741.74$13,472$627.96$536.00ABBV
3$14,628$786.85$15,906$926.08$1.3KABBV
4$16,484$831.58$19,071$1,382.55$2.6KABBV
5$18,513$875.77$23,302$2,095.81$4.8KABBV
6$20,729$919.25$29,150$3,237.93$8.4KABBV
7$23,142$961.91$37,536$5,121.41$14.4KABBV
8$25,765$1,003.62$50,079$8,338.38$24.3KABBV
9$28,613$1,044.30$69,753$14,065.80$41.1KABBV
10$31,700$1,083.86$102,337$24,771.77$70.6KABBV

TVFCF vs ABBV: Complete Analysis 2026

TVFCFStock

Télévision Française 1 Société anonyme engages in the broadcasting, studios and entertainment, and digital businesses in France and internationally. The company offers DTT channels, including TMC, TFX, and TF1 Séries Films; Theme channels, such as TV Breizh, Ushuaïa TV, and Histoire TV; e-TF1; websites; and advertising services, as well as TF1, which covers sports, French drama, news, entertainment, sports, and movies. It also operates studios, including Newen Studios; TF1 Studio; and entertainment channel comprising TF1 Entertainment. In addition, the company operates Unify, a digital channel. Further, it offers digital market consulting, digital content management, theme channel. content/broadcasting internet and TV services, and TV news images agency services. Télévision Française 1 Société anonyme was incorporated in 1982 and is based in Boulogne, France.

Full TVFCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TVFCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TVFCF vs SCHDTVFCF vs JEPITVFCF vs OTVFCF vs KOTVFCF vs MAINTVFCF vs JNJTVFCF vs MRKTVFCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.